methicillin-resistant

Nafcillin sodium monohydrate (CL 8491) is the sodium salt form of nafcillin, a semi-synthetic naphthalene, penicillin-related Nafcillin inhibits bacterial wall synthesis by a mechanism of action similar to penicillin. Penicillinase-resistant Nafcillin is used to treat infections caused by penicillin-resistant strains of Staphylococci.

MRSA antibiotic 2 is an antibiotic compound effective against various Gram-positive bacteria, including B. subtilis, S. aureus, and methicillin-resistant S. aureus (MRSA).

Cefuroxime (Cephuroxime) is an orally active second-generation cephalosporin antibiotic with antimicrobial activity that inhibits both Gram-positive and Gram-negative bacteria, and is used in the study of soft tissue infections.

Methicillin sodium salt (Meticillin sodium) is a β-lactam antibiotic (natural product), a penicillin-binding protein inhibitor (anti-Staphylococcus aureus MIC=2.1 μg/mL), used for research on Staphylococcus aureus infections and inflammation-related studies.

Linezolid (PNU-100766), the first of the oxazolidinone class, is a synthetic antibiotic used for the therapy of infections resulted from multi-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and streptococcus. The drug takes effect as the inhibitor of the initiation of bacterial protein synthesis.

Benzyldodecyldimethylammonium chloride dihydrate can be used as an insecticide reagent. It can target drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, multidrug-resistant Pseudomonas aeruginosa, etc., in a concentration-dependent manner.

VP-4604 is a potent anti-methicillin-resistant Staphylococcus aureus (MRSA) compound that exhibited significant microbial growth inhibition against S. aureus with an MIC of 4-8 μg/mL and a growth inhibition rate of over 95%.

BO3482 is an antimicrobial compound and can inhibit the growth of methicillin-resistant Staphylococci (MIC90: 6.25 mg/mL).

Afabicin is an antibiotic targeting Staphylococcus aureus, exhibiting highly effective inhibitory activity against both susceptible and methicillin-resistant (MRSA) S. aureus strains. It is used to treat acute bacterial skin and skin structure infections. Afabicin is the prodrug of Debio1452.

Tedizolid phosphate is a novel antibacterial prodrug. Tedizolid phosphate is a next-generation oxazolidinone with activity against both methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus spp. It also has effective activity a

Nafithromycin (WCK 4873) serves as an orally administered antibiotic effective against community-acquired pneumonia organisms such as Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Methicillin-susceptible Staphylococcus aureus. It displays a minimum inhibitory concentration (MIC 90) of 0.12 mg/liter against both macrolide-resistant and telithromycin-insensitive Streptococcus pneumoniae.

1-Amino-2,5-anhydro-1-deoxy-D-mannitol is a potent antibacterial compound effective against various Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Its application potential lies in its ability to combat common antibiotic-resistant bacterial infections effectively. 1-Amino-2,5-anhydro-1-deoxy-D-mannitol may emerge as a novel antimicrobial agent in clinical inhibition.

Antifungalagent 113 (compound 9a) serves as an effective antifungal and antibacterial agent. It exhibits strong inhibitory activity against both S. aureus and methicillin-resistant S. aureus.

TAN-1057C is a potent antibiotic with antimicrobial activity against both Gram-negative and Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA).

YHS-12, a ionizable cationic lipid (pKa = 6.506), has been utilized both in vitro and in vivo for delivering siRNA and mRNA via lipid nanoparticles (LNPs). These LNPs comprise YHS-12 and a targeting peptide CRVLRSGSC aimed at macrophages, encapsulating chimeric antigen receptor mRNA targeted at methicillin-resistant Staphylococcus aureus (MRSA) and siRNA against caspase-11. The LNPs have enhanced the phagocytic efficiency against MRSA in RAW 264.7 macrophages and primary murine bone marrow-derived macrophages (BMDMs). Administered intravenously, these LNPs have reduced bacterial load in the bloodstream and increased survival rates in a sepsis model in cyclophosphamide-induced immunosuppressed mice.

Antibacterialagent 119 (Compound 21 g) is a potential antibacterial agent effective against methicillin-resistant Staphylococcus aureus, with a minimum inhibitory concentration (MIC) of less than 1 μg/mL against tested strains. It induces reactive oxygen species (ROS) generation and disrupts bacterial cell membranes, causing their rupture. Antibacterialagent 119 exhibits strong antimicrobial activity, low cytotoxicity, rapid bactericidal action, and favorable in vivo antibacterial efficacy.

DNA gyrase/Topo IV-IN-1 (Compound 27) is an inhibitor of DNA gyrase and topoisomerase IV with antibacterial properties. It exhibits IC50 values of 11 and 17 nM against the DNA gyrase of Escherichia coli and methicillin-resistant Staphylococcus aureus, respectively, and IC50 values of 83 and 21 nM against topoisomerase IV of the same organisms. DNA gyrase/Topo IV-IN-1 is applicable in anti-infective research.

Anti-MRSA agent 23 (compound 11) is a potent agent against methicillin-resistant Staphylococcus aureus. This compound exhibits both antibacterial and antibiofilm properties. It facilitates the healing and reconstruction of MRSA-infected skin wounds by reducing bacterial load, alleviating inflammation, and promoting angiogenesis.

Antimicrobial agent-38 (compound 10) effectively inhibits methicillin-resistant Staphylococcus aureus (S. aureus) strain ATCC 700699 and non-resistant strain ATCC 29213, with minimum inhibitory concentrations (MIC) of 32 mg/L and 64 mg/L, respectively.

KKL-40 is a small-molecule trans-translation inhibitor that exhibits significant antibacterial activity against Staphylococcus aureus.

Antibacterialagent 267 (Compound h19) is a derivative of pleuromutilin with potent antibacterial activity against Gram-positive bacteria. It demonstrates efficacy in a mouse model infected with methicillin-resistant Staphylococcus aureus (MRSA).

C12-rrw-NH2 (Compound Lip7) is an antimicrobial agent effective against Gram-positive bacteria, particularly demonstrating significant activity against Methicillin-resistant Staphylococcus aureus (MRSA). It induces bacterial cell death by depolarizing the bacterial cell membrane, disrupting membrane integrity, causing nucleic acid and protein leakage, and promoting the generation of Reactive Oxygen Species (ROS). C12-rrw-NH2 is applicable in research focused on developing highly stable antimicrobial peptides.

Anti-MRSA agent 24 (compound 6K) is an antibacterial compound that targets methicillin-resistant Staphylococcus aureus (MRSA), demonstrating significant inhibitory effects on strains resistant to penicillin.

Deprodone is an active compound that inhibits key processes such as bacterial cell wall synthesis by interacting with hydrolase and transferase proteins of methicillin-resistant Staphylococcus aureus (MRSA). It is applied in the research of MRSA infections, inflammatory skin diseases, intestinal disorders, and fatty acid metabolism disorders.